Recent Updates
Recently added Catalysts

Nalbuphine

Phase 2

Respiratory Insufficiency | Small molecule | Other |China Pharma Holdings, Inc.|Last Updated: Jan 21, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment204
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06785571The Evaluation of the Effectiveness and Safety of Nalbuphine Hydrochloride Injection for Analgesia in ICU Patients: A Multicenter, Randomized, Single-blinded, Parallel, Two-step TrialPHASE2 RECRUITING 204Aug 30, 2023Oct 31, 2025Jan 21, 20251 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
The analgesic success rate
Within 24 hours while receiving the study drug

The analgesic success is determined as 1) no use of rescue analgesic medication and 2) at least 70% of the time with CPOT ≤ 2 points

Secondary Endpoints
The percentage of time with light sedation duration
Within 24 hours while receiving the study drug
The amout of propfol used
Within 24 hours while receiving the study drug
Successful extubation
Within 24 hours while receiving the study drug
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
lower loading dose of Nalbuphine hydrochloride for step 1EXPERIMENTALNalbuphine hydrochloride injection, a loading dose of 4 mg administered in 30 ±10 seconds, followed by a maintenance dose of 2.0mg/h (a recommended maintenance dose range of 1.0\~5.0mg/h)
higher loading dose of Nalbuphine hydrochloride for step 1EXPERIMENTALNalbuphine hydrochloride injection, a loading dose of 6 mg administered in 30 ±10 seconds, followed by a maintenance dose of 2.0mg/h (a recommended maintenance dose range of 1.0\~5.0mg/h)
Hydromorphone hydrochloride injection for step 1ACTIVE_COMPARATORHydromorphone hydrochloride injection: a maintenance dose of 0.5mg/h (a recommended maintenance dose range of 0.5\~3.0mg/h)
The optimal loading of Nalbuphine hydrochloride injection for step 2EXPERIMENTALNalbuphine hydrochloride injection: a loading dose determined after step 1 administered in 30 ±10 seconds, followed by a maintenance dose of 2.0mg/h (a recommended maintenance dose range of 1.0\~5.0mg/h)
Hydromorphone hydrochloride injection for step 2ACTIVE_COMPARATORHydromorphone hydrochloride injection: a maintenance dose of 0.5mg/h (a recommended maintenance dose range of 0.5\~3.0mg/h)
Interventions
NameTypeDescription
Nalbuphine hydrochloride injectionDRUGa loading dose of Nalbuphine hydrochloride injection administered in 30 ±10 seconds, followed by a maintenance dose of 2.0mg/h (a recommended maintenance dose range of 1.0\~5.0mg/h)
Hydromorphone hydrochloride injectionDRUGA maintenance dose of 0.5mg/h (a recommended maintenance dose range of 0.5\~3.0mg/h)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 80 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. ICU patients who are intubated are expected to require mechanical ventilation for more than 6h 2. patients or their guardians have a full understanding of the purpose and significance of this trial, and voluntarily participate in this clinical trial and sign an informed conse...

Countries:China
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06785571studyFirstPostDate: changed